Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.65 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 0.57 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6478903 | 0.87 | MAPK14 (0.70) | MAPK14 | |
| SCHEMBL6478337 | 0.87 | MAPK14 (0.61) | MAPK14RIPK3 | |
| SCHEMBL6488565 | 0.84 | MAPK14 (0.70) | MAPK14RIPK3SRCBRAFKDR | |
| SCHEMBL6479429 | 0.77 | MAPK14 (1.00) | MAPK14RIPK3 | |
| SCHEMBL6488157 | 0.76 | MAPK14 (0.71) | MAPK14RIPK3 | |
| SCHEMBL6478403 | 0.76 | MAPK14 (0.58) | MAPK14SRCBRAFKDR | |
| SCHEMBL6492214 | 0.76 | MAPK14 (0.78) | MAPK14 | |
| SCHEMBL6488506 | 0.75 | MAPK14 (0.65) | MAPK14RIPK3 | |
| SCHEMBL6480419 | 0.74 | MAPK14 (0.80) | MAPK14 | |
| SCHEMBL6490431 | 0.73 | MAPK14 (0.67) | MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919346-B2 | Isoxazolone compounds useful in treating diseases associated with unwanted cytokine activity | THE PROCTER & GAMBLE COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| US-6790846-B2 | SUCH AS 2-ETHYOXYMETHYL-4-(4-FLOUROPHENYL)-3-PYRIDIN-4-YL-2H-ISOXAZOL-5-ONE FOR INHIBITION OF THE RELEASE OF INFLAMMATORY CYTOKINES SUCH AS INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR; TREATMENT OF ARTHRITIS AND CONGESTIVE HEART FAILURE | THE PROCTER & GAMBLE COMPANY | 2004-09-14 | — | — | US | disclosed |